Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
02
09
2021
accepted:
27
12
2021
pubmed:
25
1
2022
medline:
12
4
2022
entrez:
24
1
2022
Statut:
ppublish
Résumé
Decision-making in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas depends on scaling the risk of malignancy with the surgical burden of a pancreatectomy. This study aimed to develop a preoperative, disease-specific tool to predict surgical morbidity for IPMNs. Based on preoperative variables of resected IPMNs at two high-volume institutions, classification tree analysis was applied to derive a predictive model identifying the risk factors for major morbidity (Clavien-Dindo ≥3) and postoperative pancreatic insufficiency. Among 524 patients, 289 (55.2%) underwent pancreaticoduodenectomy (PD), 144 (27.5%) underwent distal pancreatectomy (DP), and 91 (17.4%) underwent total pancreatectomy (TP) for main-duct (18.7%), branch-duct (12.6%), or mixed-type (68.7%) IPMN. For 98 (18.7%) of the patients, major morbidity developed. The classification tree distinguished different probabilities of major complications based on the type of surgery (area under the surve [AUC] 0.70; 95% confidence interval [CI], 0.63-0.77). Among the DP patients, the presence of preoperative diabetes identified two risk classes with respective probabilities of 5% and 25% for the development of major morbidity, whereas among the PD/TP patients, three different classes with respective probabilities of 15%, 20%, and 36% were identified according to age and body mass index (BMI). Overall, history of diabetes, age, and cyst size segregated three different risk classes for new-onset/worsening diabetes. In presumed IPMNs, the disease-specific risk of major morbidity and pancreatic insufficiency can be determined in the preoperative setting and used to personalize the possible surgical indication. Age and overweight status in case of PD/TP and diabetes in case of DP tip the scale toward less aggressive clinical management in the absence of features suggestive for malignancy.
Sections du résumé
BACKGROUND
BACKGROUND
Decision-making in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas depends on scaling the risk of malignancy with the surgical burden of a pancreatectomy. This study aimed to develop a preoperative, disease-specific tool to predict surgical morbidity for IPMNs.
METHODS
METHODS
Based on preoperative variables of resected IPMNs at two high-volume institutions, classification tree analysis was applied to derive a predictive model identifying the risk factors for major morbidity (Clavien-Dindo ≥3) and postoperative pancreatic insufficiency.
RESULTS
RESULTS
Among 524 patients, 289 (55.2%) underwent pancreaticoduodenectomy (PD), 144 (27.5%) underwent distal pancreatectomy (DP), and 91 (17.4%) underwent total pancreatectomy (TP) for main-duct (18.7%), branch-duct (12.6%), or mixed-type (68.7%) IPMN. For 98 (18.7%) of the patients, major morbidity developed. The classification tree distinguished different probabilities of major complications based on the type of surgery (area under the surve [AUC] 0.70; 95% confidence interval [CI], 0.63-0.77). Among the DP patients, the presence of preoperative diabetes identified two risk classes with respective probabilities of 5% and 25% for the development of major morbidity, whereas among the PD/TP patients, three different classes with respective probabilities of 15%, 20%, and 36% were identified according to age and body mass index (BMI). Overall, history of diabetes, age, and cyst size segregated three different risk classes for new-onset/worsening diabetes.
CONCLUSIONS
CONCLUSIONS
In presumed IPMNs, the disease-specific risk of major morbidity and pancreatic insufficiency can be determined in the preoperative setting and used to personalize the possible surgical indication. Age and overweight status in case of PD/TP and diabetes in case of DP tip the scale toward less aggressive clinical management in the absence of features suggestive for malignancy.
Identifiants
pubmed: 35072863
doi: 10.1245/s10434-022-11326-5
pii: 10.1245/s10434-022-11326-5
pmc: PMC8989932
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3206-3214Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Surgery. 2015 May;157(5):881-7
pubmed: 25704415
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Am J Gastroenterol. 2019 Oct;114(10):1678-1684
pubmed: 31449158
Br J Surg. 2012 Mar;99(3):404-10
pubmed: 22237731
JAMA Surg. 2018 Mar 1;153(3):225-232
pubmed: 29167899
Ann Surg. 2018 Apr;267(4):608-616
pubmed: 28594741
J Gastrointest Surg. 2015 Jun;19(6):1072-7
pubmed: 25801594
Surgery. 2013 May;153(5):641-50
pubmed: 23276391
J Am Coll Surg. 2010 Apr;210(4):463-73
pubmed: 20347739
J Am Coll Surg. 2013 Jan;216(1):1-14
pubmed: 23122535
Ann Surg. 2021 Jan 15;:
pubmed: 33630454
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Ann Surg. 2016 Jan;263(1):162-77
pubmed: 25775066
Surgery. 2007 Nov;142(5):761-8
pubmed: 17981197
HPB (Oxford). 2018 Dec;20(12):1206-1214
pubmed: 30064727
Dig Dis Sci. 2010 Mar;55(3):852-60
pubmed: 19834805
Am J Surg Pathol. 2015 Dec;39(12):1730-41
pubmed: 26559377
Int J Surg. 2013;11(9):757-61
pubmed: 23891775
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
J Gastrointest Surg. 2012 Jan;16(1):89-102; discussion 102-3
pubmed: 22065319
HPB (Oxford). 2017 Mar;19(3):264-269
pubmed: 28087319
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
JAMA Surg. 2020 Apr 1;155(4):313-321
pubmed: 32101272
HPB (Oxford). 2017 Oct;19(10):919-926
pubmed: 28754367
Dig Liver Dis. 2021 Aug;53(8):998-1003
pubmed: 33846103
Ann Surg. 2017 May;265(5):978-986
pubmed: 27232260
BJS Open. 2019 Mar 21;3(4):490-499
pubmed: 31388641